Cancer Antigen 125 Levels can be Used as a Tumor Marker for Monitoring Patients with Endometrial Serous Carcinoma?

MW Hegazy1,2*, Wael H Elsawy2, A Tolba3 and M Shoukri4

1Department of Radiation Oncology, King Faisal Specialist Hospital & Research Center, Saudi Arabia
2Department of Clinical Oncology & Nuclear Medicine, Zagazig Faculty of Medicine, Egypt
3Department of pathology, King Faisal Specialist Hospital & Research Center, Saudi Arabia
4Department of Cell Biology & Biotechnology, King Faisal Specialist Hospital & Research Center, Saudi Arabia

*Corresponding author: Mohamed W Hegazy, Department of Radiation Oncology, King Faisal Specialist Hospital & Research Center, Kingdom of Saudi Arabia, PO Box 3354, Riyadh 11211 MBC 64, Saudi Arabia, Tel: 966550742859, E-mail: mhegazy@kfshrc.edu.sa

Abstract

Aim: To determine the levels of CA-125 preoperative, postoperative and during follow up of patients with uterine serous adenocarcinoma (USAC) and evaluate its role as a tumor marker or not in these patients by its level changes on staging, cure and recurrence.

Methods: Database was reviewed for all USAC patients. Thirty three patients who were treated and had serial CA-125 (normal level up to 35 U/ml) from 2007 to 2014 at our institution were included in this study.

Results: With mean follow up of 26 months, there are 7 patients with initial normal CA-125 with only intrauterine disease and 26 patients with initial high CA-125 level with extraterine disease (p value 0.024). Mean follow up of early stage was 42 months while late stage was 20 months (p 0.019). With doubling levels of CA-125, there was a statistical significant effect on follow up period (p 0.027). In early stage, 3 out of 9 patients had recurrenc; while 13 out of 17 patients in advanced stage, post therapy after normalization of CA-125 (p = 0.04), all recurrent cases had high CA-125 (p < 0.001).

Conclusion: Our study with these findings showed that preoperative and serial levels of serum CA-125 correlate with disease stage, follow up period and may be having clinical significant and preceding disease recurrence and/or progression.

Keywords

CA125, Endometrial serous carcinoma

Background

Uterine cancer is the most common malignancy of the female genital tract in the United States [1], a situation which is similar at our institution [2].

Endometrial adenocarcinoma is the most common type of uterine cancer. Endometrial cancer is classified into two subtypes (I and II), which reflect general characteristics of its clinicopathological spectrum. Uterine serous adenocarcinoma (USAC) is under Type II neoplasms which are associated with more aggressive behavior than type I tumors. While they comprise 10-20% of endometrial carcinomas, they account for 40% of deaths from the disease [3-5].

USAC may develop from endometrial intraepithelial carcinoma (EIC), a lesion related to malignant transformation of the endometrial surface epithelium, against a background of endometrial atrophy [6,7]. However, EIC was commonly found in association with extraterine serous carcinoma, with both sites having identical clones of p53 mutations [8]. This finding suggests that EIC represents an early form of USAC rather than its true precursor [9]. A relatively new entity, “endometrial glandular dysplasia”, which histologically bridges benign endometrium and EIC, may be the putative precursor lesion to USC [10].

USAC is a more aggressive histologic variant of malignant epithelial tumors, with a higher incidence of extraterine disease at presentation [11-13]. Serous adenocarcinoma is considered high grade by default, although it is staged using the same FIGO/AIICC staging system as endometrial cancers [14]. Both the NCCN panel and the SGO recommended that CA-125 and MRI/CT may be useful before surgery to assess if extrauterine disease is present; PET may also be useful. Patterns of failure often mimic those of ovarian cancer [11]. Multimodality therapy is typically recommended for this tumors [15,16]. Optimal cytoreduction and adjuvant platinum/taxane-based chemotherapy appear to improve survival, while adjuvant radiotherapy may contribute to loco-regional disease control [11].

The 5-year survival rate for all stages of USAC is only 53% compared with 83% for endometrioid carcinoma [17]. Several studies have shown a correlation between preoperative levels of CA-125 and presence of extraterine disease at the time of surgery as well as advanced stage and survival in women with USAC [18-21]. Serum CA-125 levels in USAC have been assessed in many previous studies [19-26] and their surveillance may be a useful indicator of disease response or progression [19,26]. The aim of our study was to evaluate the clinical significance of rising CA-125 levels in patients with USAC.
Methods

The medical records of women diagnosed as USAC, had regular CA-125 levels and treated between 2007 till end of 2013 at king Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia were reviewed. Thirty three patients with histologically proven diagnosis of USAC were identified and selected for analysis. Records were reviewed for age, stage of disease, first and serial CA-125 readings (post-surgery, post chemotherapy and during follow up period). Twenty seven patients underwent comprehensive surgical staging and cytoreduction and received adjuvant treatment at our institution. Nine patients out of thirty three had second cancers (four breasts, two papillary thyroids, one skin, one hepatoma and one Non-Hodgkin’s lymphoma). The normal range of CA-125 is ≤ 35 U/mL.

Statistical Analysis

Chi square test was used to test independence between two categorical variables. Differences in median were tested using Mann-Whitney two samples test. When we have three groups or more, median test was done using Kruskal-Wallis test. Correlation between variables was assessed using Spearman’s Rank test. Type one error rate of 5% is used throughout.

Results

With a mean follow up period of 26 months [3-16], we had 33 patients of USAC. Table 1 illustrates their characteristics. Patients were under regular follow up by clinical, radiological and serial CA-125 readings (post-surgery, post chemotherapy and during follow up period). Twenty seven patients underwent comprehensive surgical staging and cytoreduction and received adjuvant treatment at our institution. Nine patients out of thirty three had second cancers (four breasts, two papillary thyroids, one skin, one hepatoma and one Non-Hodgkin’s lymphoma). The normal range of CA-125 is ≤ 35 U/mL.

<table>
<thead>
<tr>
<th>Variable</th>
<th>No.</th>
<th>%</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Age</td>
<td>69</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Age ≤ 60</td>
<td>25</td>
<td>36.8</td>
<td>0.8</td>
</tr>
<tr>
<td>&gt; 60</td>
<td>24</td>
<td>73.2</td>
<td>-</td>
</tr>
<tr>
<td>Stage 1</td>
<td>6</td>
<td>18.2</td>
<td>0.234</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>9.1</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>24.2</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>16</td>
<td>48.6</td>
<td>-</td>
</tr>
<tr>
<td>Initial CA-125 ≤ 35</td>
<td>7</td>
<td>21.2</td>
<td>0.024</td>
</tr>
<tr>
<td>&gt; 35</td>
<td>26</td>
<td>78.8</td>
<td>-</td>
</tr>
<tr>
<td>≤ 35</td>
<td>7</td>
<td>21.2</td>
<td>-</td>
</tr>
<tr>
<td>36-70</td>
<td>11</td>
<td>33.3</td>
<td>-</td>
</tr>
<tr>
<td>&gt; 70</td>
<td>15</td>
<td>45.5</td>
<td>-</td>
</tr>
<tr>
<td>Surgery</td>
<td>27</td>
<td>81.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>29</td>
<td>87.9</td>
<td>-</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>24</td>
<td>72.7</td>
<td>-</td>
</tr>
<tr>
<td>Chemotherapy alone</td>
<td>4</td>
<td>12</td>
<td>-</td>
</tr>
<tr>
<td>Mean follow up period &amp; initial CA-125 ≤ 35</td>
<td>-</td>
<td>-</td>
<td>0.001</td>
</tr>
<tr>
<td>3 (39M)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4 (16M)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Stage 1</td>
<td>6</td>
<td>18.2</td>
<td>0.249</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>9</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>24.2</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>16</td>
<td>48.5</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 1: Patients characteristics.

Discussion

In our study we tried to evaluate the potential role of CA-125 as a serum tumor marker for this uncommon high-risk endometrial cancer either in initial staging, post treatment response, disease recurrence or progression.

We found CA-125 was beneficial in three scenarios. Firstly, at diagnosis CA-125 correlated with early intrauterine and advanced extraterine stages, secondly with disease remission clinically and radiologically post treatment showed normalized CA-125, and lastly increasing in cases of recurrence and/or progression during follow up period as shown in figure 1.

No previously published studies have clearly answered the question of the role of CA-125 in USAC as shown below.

Niloff, et al. reported that CA-125 was elevated in 78% of cases with stage IV or recurrent disease [18]. Others also reported a correlation between initial high CA-125 and advanced disease at the time of surgery [27-29]. Price, et al reported that CA-125 may reflect disease stage but not disease status during follow up period [23]. Abramovich, et al reported that 73% of cases with high CA-125 correlated with clinical relapse [18]. Moller, et al. reported that initial CA-125 was not predictive for the extent of cytoreduction surgery for those cases [30]. Olawuyi, et al and Gupta, et al. concluded that CA-125 is a useful prognostic marker, as preoperative values that correlate with stage, and tumor burden, similar to our study [20,21]. Frimer, et al. reported that rising CA-125 may be clinically significant and precedes disease recurrence, and due to lack of standard biomarkers, they suggest a potential role for CA-125 to be as a monitor of surveillance for those patients in clinical remission, similar to our results [26]. Boruta, et al. have published a literature review about USAC, concluded that unlikely there have been conflicting results.
regarding to CA-125 utility, in spite of increasing CA-125 more than normal is correlated with increasing the risk of cancer related death however; CA-125 cannot be used as surrogate marker for disease status [11].

Our results are preliminary report so we have limitations like it is a retrospective review, a single institutional experience and small number of patients that may be corrected by a prospective, large, randomized multi-institutional cohort.

Conclusion

Our study with these findings showed that preoperative and serial levels of serum CA-125 correlate with disease stage, follow up period and may be having clinical significant and preceding disease recurrence and/or progression.

Compliance with Ethical Standards

This study has been approved by the institutional ethics committee and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. All persons gave their informed consent prior to therapy; however, for retrospective review of data with less than minimal risk to the patients, no consent was required by the ethics committee. All authors declare that there is no conflict of interest.

References


